Midazolam
Brand: Versed (US/EU) / Mezolam (IN) / Midatin (BD)
Sedative/Hypnotic
Benzodiazepine sedative (GABA-A positive allosteric modulator)
Pharmacokinetics
| Half-life | 3 hours |
| Tmax | 0.5 h |
| Bioavailability | 44 % (approx) |
| Protein Binding | 97 % |
| Volume of Distribution | 1.5 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Potent respiratory depressant; strong CYP3A4 metabolism; interactions with azoles, macrolides, and protease inhibitors can cause profound prolonged sedation. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Severe respiratory depression, hypotension, apnea, amnesia
Contraindications:
Acute respiratory insufficiency without airway support, shock
Precautions:
Use only with airway monitoring; avoid with potent CYP3A4 inhibitors; dose adjustment in elderly and hepatic impairment.